Earnings Summary

Beam Therapeutics Inc’s revenue jumped 20.8% since last year same period to $20.12Mn in the Q2 2023. On a quarterly growth basis, Beam Therapeutics Inc has generated -16.9% fall in its revenue since last 3-months.

Beam Therapeutics Inc’s net profit fell -15.05% since last year same period to $-82.78Mn in the Q2 2023. On a quarterly growth basis, Beam Therapeutics Inc has generated 14.19% jump in its net profits since last 3-months.

Beam Therapeutics Inc’s net profit margin jumped 4.76% since last year same period to -411.49% in the Q2 2023. On a quarterly growth basis, Beam Therapeutics Inc has generated -3.27% fall in its net profit margins since last 3-months.

Beam Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.34 - a -2.29% fall from last quarter’s estimates.

Beam Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.34.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Beam Therapeutics Inc’s return on assets (ROA) stands at -0.17.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Beam Therapeutics Inc’s return on equity (ROE) stands at -0.37.